Posted by Blue Matter on July 1st, 2019.
The Blue Matter Breakfast Club is an ongoing series of quarterly two-hour breakfast forums, hosted by our Rare Diseases Team. These forums bring together leaders from companies that develop and commercialize rare disease therapies to discuss critical business issues.
The second Breakfast Club meeting was on 17th June 2019 at Skylounge restaurant in Zug, Switzerland. The guest speaker was Nick Leschly, CEO of bluebird bio. Several key topics were raised and explored during this session, including:
- How gene therapy is finally delivering breakthroughs after a decades-long journey
- The interesting history and guiding purpose of bluebird bio
- bluebird bio’s philosophy on the value and cost of therapies
- The key challenges in unlocking the full commercial potential of gene therapies
Here, you can access an outline-based summary of the discussion: